Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
19.06.2017
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
19.06.2017
Basic Clin Pharmacol Toxicol 2017; 121:309-315
Parra-Guillen Zinnia P, Kloft Charlotte, Krähenbühl Stephan, Gillessen Sommer Silke, Früh Martin, Pfister Bogumila, Winogradova Daria, Donzelli Massimiliano, Haschke Manuel, Berger Peter B, Jörger Markus
Weiter
